Public And Private Partnerships Forge Way For China As Innovative Hub - DIA China Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - With China's government poised to invest substantial funds in coming years to encourage innovative drug development, China is quickly becoming a favorite R&D destination for multinational pharmas, but both public and private players are still grappling with how to boost R&D productivity